Palisade Bio, Inc.
corporate_fare Company Profile
Palisade Bio, Inc. (NASDAQ:PALI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for PALI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for PALI spans 10-Q, 8-K, S-3, DEFA14A.
Recent high-impact activity:
- Palisade Bio Q3 Loss Widens to $14.6M; Material Weakness Persists Despite $113.6M Cash
- Health Canada Clears Palisade Bio's Phase 2b UC Trial, Expanding Global Reach
- FDA Clears PALI-2108 for Crohn's Disease, Expanding Phase 2 Program
- Palisade Bio Advances PALI-2108 to Phase 2, Reports Q2 Results and Sets Timelines for UC and Crohn's Trials
- FDA Clears PALI-2108 for Phase 2 Ulcerative Colitis Trial, Enrollment Starts H2 2026
Financial Snapshot
Short Interest & Short Volume
7.76 days to coverFINRA reported short interest of 29,290,111 shares in PALI as of the October 30, 2026 settlement, a 7.7% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 32.1% of PALI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.